Rich-Vicks' ibuprofen/pseudoephedrine "synergy" claim "irrelevant" to patent suit -- McNeil.
This article was originally published in The Tan Sheet
Executive Summary
RICH-VICKS' IBUPROFEN/PSEUDOEPHEDRINE "SYNERGY" CLAIM "IRRELEVANT," McNEIL maintained in a brief filed with the U.S. Court of Appeals for the Federal Circuit on May 22. The document responds to Richardson-Vicks' appeal of a Jan. 17 district court decision that the Procter & Gamble unit's patent for 200 mg ibuprofen/30 mg pseudoephedrine in cough/cold products was not valid and enforceable because the combination was obvious to anyone with medical experience in the OTC cough/cold industry ("The Tan Sheet" Jan. 22, p. 1).
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning